<DOC>
	<DOCNO>NCT02371174</DOCNO>
	<brief_summary>The primary objective study clarify factor affect incidence peripheral neuropathy patient treat HALAVEN . A total 590 patient enrol study 295 patient treatment group primary secondary chemotherapy 295 patient treatment group tertiary later chemotherapy .</brief_summary>
	<brief_title>Post-Marketing Surveillance Study Eribulin Status Factors Development Peripheral Neuropathy Japan .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<criteria>Inclusion criterion : Patients HER2negative inoperable recurrent breast cancer . Exclusion criterion : Patients highgrade bone marrow depression ( absolute neutrophil count le 1,000 /mm^3 , absolute platelet count le 75,000 /mm^3 ) . Patients history hypersensitivity ingredient HALAVEN . Women pregnant may pregnant . Patients history use HALAVEN .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HER2-Negative Inoperable Recurrent Breast Cancer</keyword>
	<keyword>Japan</keyword>
	<keyword>Eribulin Mesylate</keyword>
</DOC>